ASPPH logo


Member Research & Reports

Member Research & Reports

Minnesota: New Guideline Lowers Age to Start Colon Cancer Screening to 45

In the United States, colorectal cancer is the fourth most common cancer diagnosed among adults and the second leading cause of death from cancer. An updated American Cancer Society guideline co-authored by University of Minnesota School of Public Health professor Dr. Timothy Church says colorectal cancer screening should begin at age 45 — instead of 50 — for people at average risk. The new guideline is based in part on data showing rates of colorectal cancer are increasing in young and middle-aged populations.

The updated recommendations were recently published in CA: A Cancer Journal for Clinicians, a peer-reviewed journal of the American Cancer Society.

[Photo: Dr. Tim Church]

“Colorectal cancer is becoming more prevalent in younger people,” said Dr. Church. “Asking people to begin screening at 45 rather than 50 will prevent cancer and deaths in some of those younger individuals who currently are not encouraged to get screened.

The new recommended starting age is based on colorectal cancer incidence rates and results from microsimulation modeling that shows a favorable benefit-to-burden balance of screening beginning at age 45, and the expectation that screening will perform similarly in adults ages 45 to 49 as it does in adults for whom screening is currently recommended (50 and older).

The American Cancer Society recommends:

The recommended options for colorectal cancer screening are: fecal immunochemical test (FIT) annually; high sensitivity guaiac-based fecal occult blood test (HSgFOBT) annually; multi-target stool DNA test (mt-sDNA) every 3 years; colonoscopy every 10 years; CT colonography (CTC) every 5 years; and flexible sigmoidoscopy (FS) every 5 years.

The new guideline does not prioritize among screening test options. Given the evidence that adults vary in their test preferences, the guidelines development committee emphasized that screening rates could be improved by endorsing the full range of tests without preference. The American Cancer Society has developed new materials to facilitate conversations between clinicians and patients to help patients decide which test is best for them.